Vera Therapeutics Inc [VERA] stock prices are up 5.68% to $49.1 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VERA shares have gain 5.55% over the last week, with a monthly amount glided 6.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vera Therapeutics Inc [NASDAQ: VERA] stock has seen the most recent analyst activity on October 16, 2025, when BofA Securities initiated its Buy rating and assigned the stock a price target of $48. Previously, Wolfe Research downgraded its rating to Peer Perform on August 04, 2025. Wolfe Research started tracking the stock assigning an Outperform rating and suggested a price target of $49 on February 04, 2025. Goldman initiated its recommendation with a Buy and recommended $58 as its price target on January 28, 2025. Wells Fargo started tracking with an Overweight rating for this stock on November 21, 2024, and assigned it a price target of $70. In a note dated October 16, 2024, Scotiabank initiated an Sector Outperform rating.
The stock price of Vera Therapeutics Inc [VERA] has been fluctuating between $18.53 and $56.05 over the past year. Currently, Wall Street analysts expect the stock to reach $77.6 within the next 12 months. Vera Therapeutics Inc [NASDAQ: VERA] shares were valued at $49.1 at the most recent close of the market. An investor can expect a potential return of 58.04% based on the average VERA price forecast.
Analyzing the VERA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.47 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Vera Therapeutics Inc [NASDAQ:VERA]’s Current Ratio is 12.09. Further, the Quick Ratio stands at 12.09, while the Cash Ratio is 1.46.
Transactions by insiders
Recent insider trading involved Turner William D., Chief Regulatory Officer, that happened on Dec 15 ’25 when 10000.0 shares were sold. Director, ENRIGHT PATRICK G completed a deal on Dec 11 ’25 to buy 5882.0 shares. Meanwhile, Officer WILLIAM TURNER bought 10000.0 shares on Dec 15 ’25.
